Atyr PHARMA (NASDAQ:ATYR) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Atyr PHARMA (NASDAQ:ATYR) in a report published on Thursday, Benzinga reports. The firm currently has a $35.00 price objective on the stock. HC Wainwright also issued estimates for Atyr PHARMA’s Q3 2024 earnings at ($0.22) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($0.92) EPS, FY2025 earnings at ($0.92) EPS and FY2028 earnings at $4.72 EPS.

Separately, Royal Bank of Canada restated an outperform rating and issued a $16.00 price target on shares of Atyr PHARMA in a research report on Wednesday, August 14th.

Atyr PHARMA Stock Performance

Shares of NASDAQ:ATYR opened at $1.91 on Thursday. Atyr PHARMA has a 12-month low of $1.08 and a 12-month high of $2.50. The company has a market cap of $131.81 million, a price-to-earnings ratio of -2.12 and a beta of 1.25. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.02.

Atyr PHARMA (NASDAQ:ATYR) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.01. As a group, sell-side analysts forecast that Atyr PHARMA will post -0.89 EPS for the current year.

Insider Buying and Selling

In other news, Director Paul Schimmel acquired 52,300 shares of the stock in a transaction on Wednesday, July 24th. The stock was acquired at an average cost of $1.93 per share, for a total transaction of $100,939.00. Following the completion of the transaction, the director now directly owns 413,023 shares in the company, valued at $797,134.39. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 3.70% of the stock is currently owned by company insiders.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company’s lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.